Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches

Nehad M Ayoub,1 Kamal M Al-Shami,2 Rami J Yaghan3 1Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology (JUST), Irbid, Jordan; 2Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA; 3Department of G...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ayoub NM, Al-Shami KM, Yaghan RJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Immunotherapy breast cancer HER2 checkpoint inhibitors vaccines Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5fb05676bd394ccdbb48619e7081b012
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5fb05676bd394ccdbb48619e7081b012
record_format	dspace
spelling	oai:doaj.org-article:5fb05676bd394ccdbb48619e7081b0122021-12-02T04:47:16ZImmunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches1179-1314https://doaj.org/article/5fb05676bd394ccdbb48619e7081b0122019-01-01T00:00:00Zhttps://www.dovepress.com/immunotherapy-for-her2-positive-breast-cancer-recent-advances-and-comb-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Nehad M Ayoub,1 Kamal M Al-Shami,2 Rami J Yaghan3 1Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology (JUST), Irbid, Jordan; 2Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA; 3Department of General Surgery and Urology, Faculty of Medicine, Jordan University of Science and Technology (JUST), Irbid, Jordan Abstract: Cancer immunotherapy has evolved dramatically with improved understanding of immune microenvironment and immunosurveillance. The immunogenicity of breast cancer is rather heterogeneous. Specific subtypes of breast cancer such as estrogen receptor (ER)-negative, human EGF receptor 2 (HER2)-positive, and triple-negative breast cancer (TNBC) have shown evidence of immunogenicity based on tumor–immune interactions. Several preclinical and clinical studies have explored the potential for immunotherapy to improve the clinical outcomes for different subtypes of breast cancer. This review describes the immune microenvironment of HER2-positive breast cancer and summarizes recent clinical advances of immunotherapeutic treatments in this breast cancer subtype. The review provides rationale and ongoing clinical evidence to the use of immune checkpoint inhibitors, therapeutic vaccines, and adoptive T cell immunotherapy in breast cancer. In addition, the present paper describes the most relevant clinical progress of strategies for the combination of immunotherapy with standard treatment modalities in HER2-positive breast cancer including chemotherapy, targeted therapy, and radiotherapy. Keywords: immunotherapy, breast cancer, HER2, checkpoint inhibitors, vaccinesAyoub NMAl-Shami KMYaghan RJDove Medical PressarticleImmunotherapybreast cancerHER2checkpoint inhibitorsvaccinesNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 11, Pp 53-69 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunotherapy breast cancer HER2 checkpoint inhibitors vaccines Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunotherapy breast cancer HER2 checkpoint inhibitors vaccines Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ayoub NM Al-Shami KM Yaghan RJ Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
description	Nehad M Ayoub,1 Kamal M Al-Shami,2 Rami J Yaghan3 1Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology (JUST), Irbid, Jordan; 2Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA; 3Department of General Surgery and Urology, Faculty of Medicine, Jordan University of Science and Technology (JUST), Irbid, Jordan Abstract: Cancer immunotherapy has evolved dramatically with improved understanding of immune microenvironment and immunosurveillance. The immunogenicity of breast cancer is rather heterogeneous. Specific subtypes of breast cancer such as estrogen receptor (ER)-negative, human EGF receptor 2 (HER2)-positive, and triple-negative breast cancer (TNBC) have shown evidence of immunogenicity based on tumor–immune interactions. Several preclinical and clinical studies have explored the potential for immunotherapy to improve the clinical outcomes for different subtypes of breast cancer. This review describes the immune microenvironment of HER2-positive breast cancer and summarizes recent clinical advances of immunotherapeutic treatments in this breast cancer subtype. The review provides rationale and ongoing clinical evidence to the use of immune checkpoint inhibitors, therapeutic vaccines, and adoptive T cell immunotherapy in breast cancer. In addition, the present paper describes the most relevant clinical progress of strategies for the combination of immunotherapy with standard treatment modalities in HER2-positive breast cancer including chemotherapy, targeted therapy, and radiotherapy. Keywords: immunotherapy, breast cancer, HER2, checkpoint inhibitors, vaccines
format	article
author	Ayoub NM Al-Shami KM Yaghan RJ
author_facet	Ayoub NM Al-Shami KM Yaghan RJ
author_sort	Ayoub NM
title	Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
title_short	Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
title_full	Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
title_fullStr	Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
title_full_unstemmed	Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
title_sort	immunotherapy for her2-positive breast cancer: recent advances and combination therapeutic approaches
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/5fb05676bd394ccdbb48619e7081b012
work_keys_str_mv	AT ayoubnm immunotherapyforher2positivebreastcancerrecentadvancesandcombinationtherapeuticapproaches AT alshamikm immunotherapyforher2positivebreastcancerrecentadvancesandcombinationtherapeuticapproaches AT yaghanrj immunotherapyforher2positivebreastcancerrecentadvancesandcombinationtherapeuticapproaches
_version_	1718401007744974848

Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches

Ejemplares similares